Haematological malignancies following temozolomide treatment for paediatric high-grade glioma

Karremann, Michael; Krämer, Nadja; Hoffmann, Marion; Wiese, Maria; Beilken, Andreas; Corbacioglu, Selim; Dilloo, Dagmar; Driever, Pablo Hernáiz; Scheurlen, Wolfram; Kulozik, Andreas; Gielen, Gerrit H; Von Bueren, André; Dürken, Matthias; Kramm, Christof M

doi:10.1016/j.ejca.2017.04.023

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Haematological malignancies following temozolomide treatment for paediatric high-grade glioma
Authors		Karremann, Michael Krämer, Nadja Hoffmann, Marion Wiese, Maria Beilken, Andreas Corbacioglu, Selim Dilloo, Dagmar Driever, Pablo Hernáiz Scheurlen, Wolfram Kulozik, Andreas Gielen, Gerrit H Von Bueren, André Dürken, Matthias Kramm, Christof M show all authors [1 - 14]
Published in		European Journal of Cancer. 2017, vol. 81, p. 1-8
Abstract		Temozolomide (TMZ) is widely used in high-grade glioma (HGG). There is a major concern of treatment-induced secondary haematological malignancies (SHMs). Due to the poor overall survival of HGG patients, the true incidence is yet elusive. Thus, the aim of this study was to determine the risk of SHMs following TMZ in paediatric HGG.
Keywords		Adolescent — Antineoplastic Agents — Alkylating/adverse effects — Austria/epidemiology — Child — Child — Preschool — Dacarbazine/adverse effects/analogs & derivatives — Female — Follow-Up Studies — Germany/epidemiology — Glioma/drug therapy — Hematologic Neoplasms/chemically induced/epidemiology — Humans — Incidence — Infant — Kaplan-Meier Estimate — Male — Switzerland/epidemiology
Identifiers		DOI: 10.1016/j.ejca.2017.04.023 PMID: 28586748
Full text		Article (Published version) (637 Kb) - Limited access to UNIGE
Structures		Faculté de médecine / Section de médecine clinique / Département de pédiatrie, gynécologie et obstétrique
Research group		Plateforme d'oncologie et d'hématologie pédiatrique (907)
Citation (ISO format)		KARREMANN, Michael et al. Haematological malignancies following temozolomide treatment for paediatric high-grade glioma. In: European Journal of Cancer, 2017, vol. 81, p. 1-8. https://archive-ouverte.unige.ch/unige:107413